The Tyrosine Kinase Inhibitor Dasatinib Induces a Marked Adipogenic Differentiation of Human Multipotent Mesenchymal Stromal Cells

Bone and the hematopoietic niche: a tale of two stem cells

(2011) P. Bianco   BLOOD

Combined Blockade of Src Kinase and Epidermal Growth Factor Receptor with Gemcitabine Overcomes STAT3-Mediated Resistance of Inhibition of Pancreatic Tumor Growth

(2011) N. S. Nagaraj et al.   CLINICAL CANCER RESEARCH

Human SREBP1c Expression in Liver Is Directly Regulated by Peroxisome Proliferator-activated Receptor α (PPARα)

(2011) Ana Fernández-Alvarez et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A bioinformatical and functional approach to identify novel strategies for chemoprevention of colorectal cancer

(2011) D M Heijink et al.   ONCOGENE

Nilotinib: A Novel, Selective Tyrosine Kinase Inhibitor

(2011) Jean-Yves Blay et al.   SEMINARS IN ONCOLOGY

Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer

(2011) Evan Y. Yu et al.   UROLOGY

ERK1 and ERK2 are involved in recruitment and maturation of human mesenchymal stem cells induced to adipogenic differentiation

(2011) Elisabetta Donzelli et al.   Journal of Molecular Cell Biology

The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts

(2010) Hichame Id Boufker et al.   BMC CANCER

Imatinib Mesylate Does Not Increase Bone Volume In Vivo

(2010) Susannah O’Sullivan et al.   CALCIFIED TISSUE INTERNATIONAL

Invasive Prostate Carcinoma Driven by c-Src and Androgen Receptor Synergy

(2010) H. Cai et al.   CANCER RESEARCH

Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors

(2010) John Araujo et al.   CANCER TREATMENT REVIEWS

p57 Kip2 is a downstream effector of BCR–ABL kinase inhibitors in chronic myelogenous leukemia cells

(2010) Adriana Borriello et al.   CARCINOGENESIS

Dasatinib Inhibits the Development of Metastases in a Mouse Model of Pancreatic Ductal Adenocarcinoma

(2010) Jennifer P. Morton et al.   GASTROENTEROLOGY

Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non–Small-Cell Lung Cancer

(2010) Eric B. Haura et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2010) Faye M. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

(2010) Guoqing Wei et al.   Journal of Hematology & Oncology

Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro

(2010) S Jönsson et al.   LEUKEMIA

BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review

(2010) Xin An et al.   LEUKEMIA RESEARCH

Targeted Inhibition of Src Kinase Signaling Attenuates Pancreatic Tumorigenesis

(2010) Nagathihalli S. Nagaraj et al.   MOLECULAR CANCER THERAPEUTICS

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells

(2009) G E Konecny et al.   BRITISH JOURNAL OF CANCER

Dasatinib synergizes with doxorubicin to block growth, migration and invasion of breast cancer cells

(2009) C S Pichot et al.   BRITISH JOURNAL OF CANCER

Synergistic Activity of the Src Family Kinase Inhibitor Dasatinib and Oxaliplatin in Colon Carcinoma Cells Is Mediated by Oxidative Stress

(2009) S. Kopetz et al.   CANCER RESEARCH

Decreased Bone Turnover Despite Persistent Secondary Hyperparathyroidism during Prolonged Treatment with Imatinib

(2009) Susannah O'Sullivan et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol

(2008) Alexandre Puissant et al.   FASEB JOURNAL

PPAR  and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale

(2008) M. I. Lefterova et al.   GENES & DEVELOPMENT

Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia

(2008) S. Jonsson et al.   HAEMATOLOGICA